Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Chronobiol Int ; 41(5): 609-620, 2024 May.
Article in English | MEDLINE | ID: mdl-38644696

ABSTRACT

Seasonal patterns (SP) exert a notable influence on the course and prognosis of patients with affective disorders, serving as a specifier in diagnosis. However, there is limited exploration of seasonality among psychotic patients, and the distinctions in seasonality among psychiatric patients remain unclear. In this study, we enrolled 198 psychiatric patients with anxiety and depressive disorders (A&D), bipolar disorder (BD), and schizophrenia (SZ), as well as healthy college students. Online questionnaires, including the Seasonal Pattern Assessment Questionnaire (SPAQ) for seasonality, the Morningness and Eveningness Questionnaire-5 (MEQ-5) for chronotypes, and the Pittsburgh Sleep Quality Index (PSQI), were administered. The validity and reliability of the Chinese version of the SPAQ were thoroughly analyzed, revealing a Cronbach's alpha of 0.896 with a two-factor structure. Results indicated that higher seasonality was correlated with poorer sleep quality and a more delayed chronotype (p < 0.05). Significant monthly variations were particularly evident in BD, specifically in mood, appetite, weight, social activities, and sleep dimensions (p < 0.001). In summary, the Chinese version of SPAQ is validated, demonstrating moderate correlations between seasonality, chronotype, and sleep quality. BD patients exhibited the strongest seasonality, while mood disorder patients displayed more delayed chronotypes than SZ.


Subject(s)
Circadian Rhythm , Seasons , Humans , Male , Female , Surveys and Questionnaires , Adult , Circadian Rhythm/physiology , Young Adult , Middle Aged , Reproducibility of Results , Asian People , Bipolar Disorder/diagnosis , Bipolar Disorder/physiopathology , Sleep/physiology , Sleep Quality , China/epidemiology , Schizophrenia/physiopathology , Schizophrenia/diagnosis , Mental Disorders/diagnosis , Mental Disorders/physiopathology , Adolescent
2.
BMC Psychiatry ; 24(1): 130, 2024 Feb 16.
Article in English | MEDLINE | ID: mdl-38365634

ABSTRACT

BACKGROUND: Electroconvulsive therapy (ECT) is a highly effective treatment for depressive disorder. However, the use of ECT is limited by its cognitive side effects (CSEs), and no specific intervention has been developed to address this problem. As transcranial direct current stimulation (tDCS) is a safe and useful tool for improving cognitive function, the main objective of this study was to explore the ability to use tDCS after ECT to ameliorate the cognitive side effects. METHODS: 60 eligible participants will be recruited within two days after completing ECT course and randomly assigned to receive either active or sham stimulation in a blinded, parallel-design trial and continue their usual pharmacotherapy. The tDCS protocol consists of 30-min sessions at 2 mA, 5 times per week for 2 consecutive weeks, applied through 15-cm2 electrodes. An anode will be placed over the left dorsolateral prefrontal cortex (DLPFC), and a cathode will be placed over the right supraorbital cortex. Cognitive function and depressive symptoms will be assessed before the first stimulation (T0), after the final stimulation (T1), 2 weeks after the final stimulation (T2), and 4 weeks after the final stimulation (T3) using the Cambridge Neuropsychological Test Automated Battery (CANTAB). DISCUSSION: We describe a novel clinical trial to explore whether the administration of tDCS after completing ECT course can accelerates recovery from the CSEs. We hypothesized that the active group would recover faster from the CSEs and be superior to the sham group. If our hypothesis is supported, the use of tDCS could benefit eligible patients who are reluctant to receive ECT and reduce the risk of self-inflicted or suicide due to delays in treatment. TRIAL REGISTRATION DETAILS: The trial protocol is registered with https://www.chictr.org.cn/ under protocol registration number ChiCTR2300071147 (date of registration: 05.06.2023). Recruitment will start in November 2023.


Subject(s)
Electroconvulsive Therapy , Transcranial Direct Current Stimulation , Humans , Transcranial Direct Current Stimulation/methods , Electroconvulsive Therapy/adverse effects , Depression/therapy , Prefrontal Cortex/physiology , Cognition , Double-Blind Method , Randomized Controlled Trials as Topic
3.
Ann Med ; 55(2): 2240422, 2023.
Article in English | MEDLINE | ID: mdl-37506182

ABSTRACT

Introduction: Bipolar disorder (BD) is a prevalent and disabling mental disorder characterized by disrupted circadian rhythms and impaired neurocognitive features, both of which fall under the major domains of Research Domain Criteria (RDoC). However, there is limited evidence regarding the interaction between circadian rhythms and long-term neurocognitive functioning. Therefore, this longitudinal cohort study protocol aims to explore whether circadian rhythm can predict changes in neurocognitive functioning over time in patients with BD.Methods: This study adopts a longitudinal cohort design, aiming to recruit 100 BD patients in either depressive or remitted states. Participants will undergo evaluations from clinical, circadian rhythm, and neurocognitive perspectives at baseline, 6-month, and 12-month follow-ups, involving questionnaires, actigraphy, and computed neurocognitive tests. We will examine both cross-sectional and longitudinal associations between participants' circadian rhythm patterns and neurocognitive functioning. Statistical analyses will employ Spearman correlation and mixed regression models.Discussion: We anticipate that circadian rhythms may serve as predictors of neurocognitive functioning changes. The findings of this study could offer supplementary insights into BD pathophysiology, potential treatment targets, and prediction.Trial Registration: This study has been registered with the Chinese Clinical Trial Registry under the registration code ChiCTR2200064922 on 21st October 2022.


Subject(s)
Bipolar Disorder , Humans , Bipolar Disorder/complications , Longitudinal Studies , Cross-Sectional Studies , Circadian Rhythm/physiology , Cohort Studies
4.
Front Psychiatry ; 14: 1145964, 2023.
Article in English | MEDLINE | ID: mdl-37363166

ABSTRACT

Background: Criterion A changes for bipolar disorder (BD) in the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition yield new difficulties in diagnosis. Actigraphy has been used to capture the activity features of patients with BD. However, it remains unclear whether long-term actigraphic data could distinguish between different mood states in hospitalized patients with BD. Methods: In this observational study, 30 hospitalized patients with BD were included. Wrist-worn actigraphs were used to monitor motor activity. The patients were divided into bipolar disorder-depression (BD-D), bipolar disorder-mania (BD-M), and bipolar disorder-mixed state (BD-MS) groups. Motor activity differences were estimated using non-parametric analyses between and within the three groups. Results: The mean 24 h activity level differed between the groups. In the between-group analysis, the intra-individual fluctuation and minute-to-minute variability in the morning and the mean activity level and minute-to-minute variability in the evening significantly differed between the BD-M and BD-MS groups. In the within-group analysis, the BD-M group showed a disrupted rhythm and reduced activity complexity at night. Both the BD-D and BD-MS groups demonstrated significant differences between several parameters obtained in the morning and evening. Conclusion: The mean activity levels during the relatively long monitoring period and the intra-day variation within the groups could reflect the differences in motor activity. Sustained activity monitoring may clarify the emotional states and provide information for clinical diagnosis.

5.
BMC Psychiatry ; 23(1): 129, 2023 03 01.
Article in English | MEDLINE | ID: mdl-36859183

ABSTRACT

BACKGROUND: Subacute combined degeneration of the spinal cord (SCD) is mainly caused by deficiency of Vitamin B12 and characterized by deep hypoesthesia, sensory ataxia and spasmodic paralysis of lower limbs. SCD often accompanies with megaloblastic anemia. Psychiatric symptoms could be the initial manifestations of SCD by lack of Vitamin B12, but are rarely considered secondary to physical discomfort and psychological factors in SCD. Additionally, treatment experience for psychiatric symptoms in SCD remains little reported. CASE REPORT: We presented a case of a 37-year-old female who complained of being persecuted and controlled for one week and thus was admitted to the psychiatry department. Before that, she had went through persistent paresthesia and numbness of her lower extremities for two-month. Low Vitamin B12 level and hemoglobin concentration, neurologic symptoms and bone marrow smear results supported the clinical diagnosis of SCD and megaloblastic anemia. With supplementation of Vitamin B12 and blood transfusion and short-term prescription of antipsychotics and antidepressants, physical symptoms were improved and psychological symptoms disappeared within 2 weeks. CONCLUSIONS: Psychiatric symptoms of SCD could be generated from lack of Vitamin B12, anemia and neurologic symptoms, where short-term use of antipsychotics and antidepressants may be effective.


Subject(s)
Anemia, Megaloblastic , Antipsychotic Agents , Subacute Combined Degeneration , Female , Humans , Adult , Hospitalization
6.
Nat Prod Res ; 37(8): 1265-1270, 2023 Apr.
Article in English | MEDLINE | ID: mdl-34727810

ABSTRACT

A step-economical synthesis of (-)-15-oxopuupehenol from cheap and readily available (+)-sclarelide is achieved with 20.3% overall yield in 9 steps. The key features of this synthetic mythology include a palladium catalyzed tandem carbine migratory insertion reaction to construct the key skeleton, a DDQ-mediated isomerization/oxidation of allyl alcohol to afford α, ß-unsaturated ketone, and a NaOH-induced intramolecular Michael addition followed by acetonide deprotection to give (-)-15-oxopuupehenol.


Subject(s)
Biological Products , Diterpenes , Stereoisomerism , Catalysis
7.
Front Psychiatry ; 13: 1011978, 2022.
Article in English | MEDLINE | ID: mdl-36458119

ABSTRACT

Introduction: Bipolar disorder (BD) is a common and debilitating mental illness that affects about 400 million people worldwide, decreasing their functionality and quality of life. Medication and psychotherapy are recommended for treatment of BD, while some evidence indicates that exercise could improve the clinical outcome of BD. This study aims to investigate whether exercise intervention could reduce the mood symptoms and inflammation level of BD. Methods: This is a longitudinal, interventional, randomized, and single-blind trial. We plan to recruit 94 patients diagnosed with BD in depression episode. Patients will be randomly assigned to treatment as usual + aerobic exercise group (intervention group) and treatment as usual (TAU) only group, at a ratio of 1:1. The intervention group will undergo 40-min aerobic exercise training twice a week for eight weeks. The primary outcome of this study is the mean change of Hamilton Depression Rating Scale 17 (HAMD 17) scores from baseline to week 8. The Young Manic Rating Scale (YMRS), Self-Rating Depression Scale (SDS), and Interleukin-6 (IL-6), Tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) levels will also be measured. The measurements will be performed at baseline, immediately after intervention and two months after intervention. Discussion: Aerobic exercise training + treatment is expected to bring more benefits to BD patients than TAU only. This trial might provide stronger evidence of physical exercise efficacy for BD treatment. Clinical trial registration: This study was approved by the Chinese Clinical Trial Registry (Registration Code: ChiCTR2200057159). Registered on 1 March 2022.

8.
Bioorg Med Chem Lett ; 23(6): 1676-9, 2013 Mar 15.
Article in English | MEDLINE | ID: mdl-23411077

ABSTRACT

In an effort to prepare a fluorogenic substrate to be used in activity assays with metallo-ß-lactamases, (6R,7R)-8-oxo-7-(2-oxo-2H-chromene-3-carboxamido)-3-((4-(2-oxo-2H-chromene-3-carboxamido)-phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (CA) was synthesized and characterized. CA exhibited a fluorescence quantum yield (φ) of 0.0059, two fluorescence lifetimes of 3.63×10(-10) and 5.38×10(-9)s, and fluorescence intensity that is concentration-dependent. Steady-state kinetic assays revealed that CA is a substrate for metallo-ß-lactamases (MßLs) L1 and CcrA, exhibiting Km and kcat values of 18µM and 5s(-1) and 11µM and 17s(-1), respectively.


Subject(s)
Azabicyclo Compounds/chemistry , Coumarins/chemistry , Fluorescent Dyes/chemistry , Zinc/chemistry , beta-Lactamases/metabolism , Azabicyclo Compounds/chemical synthesis , Azabicyclo Compounds/metabolism , Coumarins/chemical synthesis , Coumarins/metabolism , Kinetics , Spectrophotometry, Ultraviolet , Stereoisomerism , Substrate Specificity , beta-Lactamases/chemistry
9.
Sheng Wu Gong Cheng Xue Bao ; 19(3): 372-5, 2003 May.
Article in Chinese | MEDLINE | ID: mdl-15969025

ABSTRACT

It was clearly demonstrated that T-DNA of Agrobacterium tumefeciens Ti plasmid was integrated into the cells of crown gall in our experiment. This paper reported the influences of some kinds of physical-chemistry factors on the growth of crown gall of Panax quinquefolium and the production of its main active compounds--ginsenoside Re and ginsensoside Rg1. The results showed that White medium was the best one for ginsensoside Rg1 accumulation (0.095%) among the six media, but ginsensoside Re accumulation (0.194%) was the highest on the MS medium; The highest contents of ginsensoside Re (0.147%) and ginsensoside Rg1 (0.061%) were on the culture 36d and 32d after innoculum respectively; The optimum pH was 5.6 for ginsensoside Rg1 synthesis(0.054%), and 5.8 for ginsensoside Re synthesis(0. 184% ); The contents of ginsensoside Re and ginsensoside Rg1 was the highest in the inoculum of 4 g and 2 g/flask (FW) respectively. The result also indicated that the concentration of inositol in 0.05 g/L could obviously promote ginsensoside Re synthesis (0.182%), and in 0.30 g/L for ginsensoside Rg1 (0.055%).


Subject(s)
Ginsenosides/biosynthesis , Panax/growth & development , Panax/metabolism , Plant Tumors/microbiology , Agrobacterium tumefaciens/genetics , Agrobacterium tumefaciens/physiology , Cell Culture Techniques , Hydrogen-Ion Concentration , Panax/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...